Streetbeat News

Analyst Ratings

CON

Concentra Group Holdings shares fell after B of A Securities downgraded the stock from Buy to Neutral and reduced its price target from $30.5 to $24.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:45 pm

BMY

Barclays analyst Carter Gould maintains an Underweight rating on Bristol-Myers Squibb (NYSE:BMY) but raises the price target from $42 to $43.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:42 pm

ACCD

Accolade shares are experiencing an upward trend following Needham's reiteration of a Buy rating and a maintained price target of $8.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:41 pm

MRK

Barclays analyst Carter Gould maintains an Overweight rating on Merck & Co (NYSE:MRK) but lowers the price target from $142 to $140.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:41 pm

MSTR

Bernstein analysts project a 64% upside for MicroStrategy's stock, setting a $290 price target based on its Bitcoin acquisition strategy. The company's substantial Bitcoin holdings and the assumption of Bitcoin reaching $1 million by 2033 underpin this optimistic outlook. However, risks include potential Bitcoin price stagnation, which could force asset sales.

Portfolio Pulse from Ivan Crnogatić

October 07, 2024 | 6:40 pm

PLAY

Dave & Buster's Entertainment shares are experiencing a decline after Benchmark initiated coverage with a Hold rating.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:39 pm

GILD

Barclays analyst Carter Gould maintains an Equal-Weight rating on Gilead Sciences and raises the price target from $76 to $84.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:39 pm

ZVRA

Zevra Therapeutics shares rose following Guggenheim's initiation of coverage with a Buy rating and a $20 price target.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:38 pm

NFLX

Netflix shares are trading lower due to a downgrade from Barclays, which cited valuation concerns. Barclays downgraded Netflix from Equal-Weight to Underweight, maintaining a price target of $550. Despite this, Goldman Sachs and Piper Sandler have positive outlooks, with Piper Sandler upgrading Netflix to Overweight and raising the price target to $800.

Portfolio Pulse from Adam Eckert

October 07, 2024 | 6:37 pm

VRNS

Barclays analyst Saket Kalia maintains an Overweight rating on Varonis Systems and raises the price target from $60 to $65.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 6:36 pm